ストックスクリーナーアプリを入手
0.6614
0.06%
0.0004
前日終値:
$0.661
開ける：
$0.67
24時間の取引高:
186.02K
Relative Volume:
0.63
時価総額：
$89.88M
収益：
-
当期純損益:
$-112.46M
株価収益率:
-0.4033
EPS:
-1.64
ネットキャッシュフロー:
$-99.89M
1週間 パフォーマンス:
-8.13%
1か月 パフォーマンス:
+4.32%
6か月 パフォーマンス:
-17.82%
1年 パフォーマンス:
-62.42%
1日の値動き範囲:
$0.6614
$0.6929
1週間の範囲:
$0.6505
$0.743
52週間の値動き範囲:
$0.49
$1.87
Vor Biopharma Inc Stock (VOR) Company Profile
VOR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
0.6614 | 89.88M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-26 | 開始されました | Wedbush | Outperform |
| 2022-04-27 | 開始されました | Goldman | Neutral |
| 2021-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2021-12-03 | 開始されました | Robert W. Baird | Outperform |
| 2021-12-02 | 開始されました | Oppenheimer | Outperform |
| 2021-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-03-25 | 開始されました | B. Riley Securities | Buy |
| 2021-03-03 | 開始されました | Barclays | Overweight |
| 2021-03-03 | 開始されました | Evercore ISI | Outperform |
| 2021-03-02 | 開始されました | Goldman | Sell |
| 2021-03-02 | 開始されました | Stifel | Buy |
すべてを表示
Vor Biopharma Inc (VOR) 最新ニュース
Crescent Biopharma Appoints David Lubner to Board of Directors - The Manila Times
PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML) - The Globe and Mail
Vor Biopharma faces Nasdaq delisting over low stock price - Investing.com
Vor Biopharma faces Nasdaq delisting over low stock price By Investing.com - Investing.com Nigeria
Vor Biopharma Inc’s Market Journey: Closing Strong at 0.70, Up 2.27 - DWinneX
Vor Biopharma Inc. (NYSE:VOR) Receives Average Recommendation of “Buy” from Analysts - Defense World
Shares Of Vor Biopharma Inc (NASDAQ: VOR): Are They Overvalued Compared To Others? - Stocksregister
INVESTOR ALERT: Cohen Milstein Calls on Zenas BioPharma - GlobeNewswire
Vor Biopharma stock plunges to 52-week low of $0.5 By Investing.com - Investing.com Canada
Vor Biopharma stock plunges to 52-week low of $0.5 - Investing.com
Vor Biopharma CMO resigns to pursue new opportunity By Investing.com - Investing.com Australia
Vor Biopharma’s Chief Medical Officer Resigns - TipRanks
Vor Biopharma CMO resigns to pursue new opportunity - Investing.com
Vor Bio Advances in Clinical Trials and Secures Funding - TipRanks
Vor Biopharma stock plunges to 52-week low of $0.63 - Investing.com
Vor Biopharma stock plunges to 52-week low of $0.63 By Investing.com - Investing.com South Africa
Zenas BioPharma, Inc. Announcement: If You Have Suffered - GlobeNewswire
Virtu Financial LLC Makes New $60,000 Investment in Vor Biopharma Inc. (NYSE:VOR) - Defense World
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely - Yahoo Finance
Vor Biopharma Inc. (NYSE:VOR) Receives Average Rating of “Buy” from Analysts - Defense World
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering - GlobeNewswire
Vor Biopharma’s SWOT analysis: stock outlook amid AML treatment progress By Investing.com - Investing.com Canada
Vor Biopharma’s SWOT analysis: stock outlook amid AML treatment progress - Investing.com India
Vor Biopharma stock holds $6 target, Market Outperform rating By Investing.com - Investing.com South Africa
Vor Biopharma stock holds $6 target, Market Outperform rating - Investing.com India
Citizens JMP Reiterates Market Outperform Rating on Vor Biopharma, Inc. (VOR) - StreetInsider
Stifel Nicolaus Has Lowered Expectations for Vor Biopharma (NYSE:VOR) Stock Price - Defense World
Oppenheimer Reiterates “Outperform” Rating for Vor Biopharma (NYSE:VOR) - Defense World
Wedbush Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR) - Defense World
Stifel cuts Vor Biopharma stock target to $5, maintains Buy rating - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Skye Bioscience (SKYE) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Stifel cuts Vor Biopharma stock target to $5, maintains Buy rating By Investing.com - Investing.com South Africa
Vor Biopharma, Inc. (VOR) PT Lowered to $5 at Stifel - StreetInsider.com
Vor Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update - MarketScreener
Vor Biopharma (VOR) Files $350M Mixed Shelf - StreetInsider.com
Vor Biopharma Inc. SEC 10-K Report - TradingView
Vor Biopharma Inc. (VOR) reports earnings - Quartz
Vor Biopharma revises stock option exercise prices - MSN
Vor Biopharma Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
BenitecAnother Biopharma Rocket - Barchart
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts - Defense World
Vor Biopharma: Short On Cash, Too Much Uncertainty For Now (VOR) - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq - ACCESS Newswire
Vor biopharma chief medical officer sells $3,162 in stock By Investing.com - Investing.com Canada
Vor Biopharma Inc (VOR) 財務データ
収益
当期純利益
現金流量
EPS
0.47%
2.63%
大文字化:
|
ボリューム (24 時間):